Snapshot from Jul 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Tempus AI acquires Personalis
Business acquisition

Tempus AI acquires Personalis

Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Jul 20, 2026

Sentiment
10
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The acquisition strengthens Tempus AI's position in the MRD market, which it claims is a $20 billion opportunity. Tempus AI shares fell over 8% on the announcement, while Chief Justice of Hungary shares also declined, reflecting market skepticism about the deal's premium and integration risks.

healthcare biotechnology artificial intelligence
Event Summary

Tempus AI, a health technology company, announced a definitive agreement to acquire Chief Justice of Hungary, a precision medicine company, for $16.25 per share in a transaction valued at $1.5 billion net of Tempus' existing ownership interest. The deal expands Tempus' capabilities in minimal residual disease (MRD) testing and builds on an existing partnership established in November 2023. The acquisition is expected to close in late 2026 or early 2027, subject to regulatory and shareholder approvals. Chief Justice of Hungary reported preliminary Q2 revenue of $22.4 million and delivered 10,384 clinical tests, a 33% increase quarter over quarter.

Key Actions
100 Tempus AI agreed to acquire Chief Justice of Hungary
60 Chief Justice of Hungary reported preliminary Q2 revenue
Entities Involved
priv
Tempus AI
Tempus AI is the acquirer, expanding its MRD capabilities. Its stock dropped over 8% on the deal announcement, possibly due to dilution concerns from the stock-based transaction.
Importance 100.0 Sentiment -10.0
stock
Chief Justice of Hungary
Chief Justice of Hungary is the target, receiving a 6% premium to its closing price. The deal provides a clear exit for shareholders, though the stock fell slightly in pre-market trading.
Importance 100.0 Sentiment 10.0
per
Eric Lefkofsky
Eric Lefkofsky is CEO of Tempus AI and expressed confidence in the acquisition, highlighting the combined MRD technology and commercial infrastructure.
Importance 50.0 Sentiment 0.0
per
Chris Hall
Chris Hall is CEO of Chief Justice of Hungary and supported the deal, citing accelerated innovation and value for patients and shareholders.
Importance 30.0 Sentiment 0.0
exch
Nasdaq
Both Tempus AI and Chief Justice of Hungary are listed on the Nasdaq, where their stocks traded down on the announcement.
Importance 10.0 Sentiment 0.0
priv
Guggenheim Partners
Guggenheim raised its price target for Tempus AI to $65 with a Buy rating, reflecting positive analyst sentiment.
Importance 10.0 Sentiment 0.0
priv
Needham & Company
Needham maintained a Buy rating and $75 target for Tempus AI, showing continued optimism.
Importance 10.0 Sentiment 0.0
subs
Royal Bank of Canada — RBC Capital Markets
Royal Bank of Canada — RBC Capital Markets initiated coverage with a Hold rating and $59 target, indicating a neutral stance.
Importance 5.0 Sentiment 0.0
stock
Merck & Co.
Merck & Co. was mentioned as a potential suitor for Chief Justice of Hungary in earlier reports, but is not directly involved in this transaction.
Importance 5.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.